Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].

Le Pen C, Lilliu H, Allicar MP, Olivier V, Gregor KJ.

Encephale. 1999 Jul-Aug;25(4):281-6. French.

PMID:
10546082
2.

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G.

Pharmacoeconomics. 1999 May;15(5):469-80.

PMID:
10537964
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.

Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine..

JAMA. 2003 Nov 26;290(20):2693-702.

PMID:
14645311
5.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
6.

Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.

Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK.

J Clin Psychiatry. 1999;60 Suppl 19:38-45; discussion 46.

7.

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.

Glazer WM, Johnstone BM.

J Clin Psychiatry. 1997;58 Suppl 10:50-4. Review.

8.

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].

Sacristán JA, Gómez JC, Salvador-Carulla L.

Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997 Jul-Aug;25(4):225-34. Spanish.

PMID:
9412161
9.
10.

Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Foster RH, Goa KL.

Pharmacoeconomics. 1999 Jun;15(6):611-40. Review.

PMID:
10538333
11.

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.

Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.

Schizophr Res. 2003 Jun 1;61(2-3):303-14.

PMID:
12729882
13.

A cost-effectiveness clinical decision analysis model for schizophrenia.

Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.

Am J Manag Care. 1998 Mar;4(3):345-55.

14.

Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.

Hamilton SH, Edgell ET, Revicki DA, Breier A.

Int Clin Psychopharmacol. 2000 Sep;15(5):245-55.

PMID:
10993126
15.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
16.

Olanzapine versus haloperidol treatment in first-episode psychosis.

Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD.

Am J Psychiatry. 1999 Jan;156(1):79-87.

PMID:
9892301
17.

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A.

Pharmacoeconomics. 2000 Dec;18(6):567-79.

PMID:
11227395
18.
19.

A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.

Palmer CS, Brunner E, Ruíz-Flores LG, Paez-Agraz F, Revicki DA.

Arch Med Res. 2002 Nov-Dec;33(6):572-80.

PMID:
12505105
20.
Items per page

Supplemental Content

Support Center